Imipenem/Cilastatin Fresenius Kabi

Imipenem/Cilastatin, the active ingredient in Imipenem/Cilastatin Fresenius Kabi, is a carbapenem antibiotic presented as a sterile powder for intravenous infusion use. It treats a range of serious bacterial infections in hospitalized adults and children when other agents are unsuitable. GNH USA supplies Imipenem/Cilastatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for severe bacterial infections across several organ systems.

Complicated intra‑abdominal infection: provides rapid bacterial eradication to resolve intra‑abdominal sepsis. Complicated urinary tract infection: eliminates resistant uropathogens causing pyelonephritis and cystitis. Complicated skin and soft tissue infection: treats deep tissue infections where Gram‑negative and anaerobic coverage is needed. Hospital‑acquired and ventilator‑associated pneumonia: offers coverage against multidrug‑resistant respiratory pathogens. Severe sepsis and septic shock: delivers timely bactericidal activity to improve outcomes in systemic infection.

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves without intervention. - Infusion site phlebitis: local irritation at the IV site. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated colitis presenting with profuse diarrhea. - Neutropenia or thrombocytopenia: significant drops in blood cell counts. - Renal toxicity: worsening kidney function in susceptible individuals.

Careful assessment and monitoring are required before and during therapy.

Renal function: adjust dose in patients with impaired kidney function. Seizure risk: monitor patients with a history of seizures or CNS disorders. Allergy: avoid in individuals with known hypersensitivity to carbapenems. Drug interactions: review concomitant medications that may lower seizure threshold. Pregnancy and lactation: use only when the potential benefit justifies the potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/Cilastatin may interact with several agents; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Valproic acid: may reduce imipenem plasma concentrations, compromising efficacy. - Cisplatin: concurrent use can increase nephrotoxicity. - Other carbapenems: redundant therapy may increase toxicity without added benefit.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate renal impairment. - Phenobarbital: may lower seizure threshold when combined. - Other nephrotoxic drugs (e.g., aminoglycosides): monitor renal function closely.